GlassScriptPhysician profile
Kevin Ronald Olson
NPI 1578555975
$7,925.77
in general payments reported to CMS, 2019-2025
58 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $363 · 2021: $1,299 · 2022: $1,294 · 2023: $1,604 · 2024: $1,390 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027 · Education: $43.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,026.98 |
| Education | $43.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.55 | 2019-2025 | |
| Lilly USA, LLC | $1,039.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $779.18 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $732.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.35 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $371.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.84 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $215.98 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $208.92 | 2019-2024 | Capvaxive |
| Janssen Pharmaceuticals, INC | $208.35 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $198.40 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $185.23 | 2019-2023 | Prolia, Evenity |
| Amarin Pharma, INC. | $183.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $178.96 | 2022-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $118.66 | 2019-2025 | Zoryve |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.